Bcr-Abl
| 货号 | 产品名 | CAS号 | 信息 |
|---|---|---|---|
| FB01232 | WP1130 | 856243-80-6 | WP1130 is a selective small molecular deubiquitinase (USP5, UCH-L1, USP9x, USP14, and UCH37) inhibitor and a Bcr/Abl destruction pathway activator with an IC50 of 1.8 μM for K562 cells. |
| FB11913 | SNIPER(ABL)-062 | 2140260-89-3 | SNIPER(ABL)-062 is a potent SNIPER molecule that tethers BCR-ABL inhibitor to a ligand of IAP, causes potent BCR-ABL degradation; shows desirable binding affinities against ABL1, cIAP1/2, and XIAP (IC50=80-500 nM), inhibits BCR-ABL-mediated signaling pathways and CML proliferation in cells expressing BCR-ABL. |
| FB19577 | SIAIS178 | 2376047-73-1 | SIAIS178 is a potent and selective BCR-ABL degrader based on PROTAC technology with an IC50 of 24 nM. SIAIS178 causes effective degradation of BCR-ABL protein by recruiting Von Hippel-Lindau (VHL) E3 ubiquitin ligase. SIAIS178 has anticancer activity. |
| FB06958 | Radotinib | 926037-48-1 | Radotinib is a selective BCR-ABL1 inhibitor with IC50 of 34 nM, also inhibits platelet-derived growth factor receptor (PDGFR), is used to treat cancers and Chronic Myeloid Leukemia. |
| FB12098 | Target Protein-binding Moiety 8 | 910297-51-7 | PROTAC Bcr-Abl-binding moiety 1 is a Dasatinib-based warhead ligand for conjugation reactions of PROTAC targeting on Bcr-Abl. |
| FB12618 | PPY A | 875634-01-8 | PPY A is a potent inhibitor of T315l mutant and wild-type Abl kinases with IC50s of 9 and 20 nM, respectively. |
| FB02438 | Ponatinib | 943319-70-8 | Ponatinib is a potent multi-target inhibitor of Abl, PDGFRα, VEGFR2, FGFR1 and Src with IC50 of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM and 5.4 nM, respectively. |
| FB07592 | Nilotinib | 641571-10-0 | Nilotinib is a Bcr-Abl inhibitor with IC50 less than 30 nM in Murine myeloid progenitor cells. |
| FB01753 | Nilotinib HCl H2O | 923288-90-8 | Nilotinib HCl is a Bcr-Abl inhibitor with IC50 < 30 nM. |
| FB03114 | Lyn-IN-1 | 887650-05-7 | Lyn-IN-1 is a potent and selective dual Bcr-Abl/Lyn inhibitor with potential antineoplastic activity, it is an orally bioavailable 2-phenylaminopyrimidine derivative. |
| FB02681 | GZD824 | 1257628-77-5 | GZD824 is an orally bioavailable Bcr-Abl inhibitor for Bcr-Abl (WT) and Bcr-Abl (T315I) with IC50 of 0.34 and 0.68 nM, respectively. |
| FB09947 | GZD824 Dimesylate | 1421783-64-3 | GZD824 dimesylate is an orally bioavailable Bcr-Abl inhibitor for Bcr-Abl (WT) and Bcr-Abl (T315I) with IC50 of 0.34 nM and 0.68 nM, respectively. |
| FB07037 | GNF-7 | 839706-07-9 | GNF-7 inhibits Bcr-Abl WT and Bcr-Abl T315I with IC50 of 133 nM and 61 nM, respectively. |
| FB04099 | GNF-5 | 778277-15-9 | GNF-5 is a selective non-ATP competitive inhibitor of Bcr-Abl with IC50 of 220 nM, it's an analogue of GNF-2 with improved pharmacokinetic properties. |
| FB00766 | GNF-2 | 778270-11-4 | GNF-2 is a highly selective non-ATP competitive inhibitor of oncogenic Bcr-Abl activity (IC50 = 0.14 μM). |
| FB16755 | GMB-475 | 2490599-18-1 | GMB-475 is a degrader of BCR-ABL1 tyrosine kinase based on PROTAC, overcoming BCR-ABL1-dependent drug resistance. GMB-475 reduced viability and increased apoptosis in primary CML CD34+ cells, with no effect on healthy CD34+ cells at identical concentrations. |
| FB01144 | Flumatinib Mesylate | 895519-91-2 | Flumatinib mesylate, a derivative of imatinib, is a multi-kinase inhibitor with IC50 Values of 1.2 nM, 307.6 nM and 2662 nM for c-Abl, PDGFRβ and c-Kit respectively. |
| FB06908 | Flumatinib | 895519-90-1 | Flumatinib is a multi-kinase inhibitor with IC50 Values of 1.2 nM, 307.6 nM and 2662 nM for c-Abl, PDGFRβ and c-Kit respectively. |
| FB02937 | DPH | 484049-04-9 | DPH is a potent cell permeable c-Abl activator, which displays potent enzymatic and cellular activity in stimulating c-Abl activation. |
| FB06545 | DCC-2036 | 1020172-07-9 | DCC-2036 is a conformational control Bcr-Abl inhibitor for Abl1 (WT) and Abl1 (T315I) with IC50 of 0.8 nM and 4 nM, also inhibits SRC, LYN, FGR, HCK, KDR, FLT3, and Tie-2. |
| FB10533 | Dasatinib Monohydrate | 863127-77-9 | Dasatinib is a potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of < 1 nM, 0.8 nM and 79 nM, respectively. |
| FB10589 | Dasatinib | 302962-49-8 | Dasatinib is a potent and dual Abl/ Src inhibitor IC50 of < 1 nM/0.8 nM respectively and also inhibits c-Kit (WT)/c-Kit (D816V) with IC50 of 79 nM/37 nM. |
| FB06846 | Dasatinib HCl | 854001-07-3 | Dasatinib HCl is a potent and dual Abl/ Src inhibitor IC50 of < 1 nM/0.8 nM respectively and also inhibits c-Kit (WT)/c-Kit (D816V) with IC50 of 79 nM/37 nM. |
| FB17964 | CZC-8004 | 916603-07-1 | CZC-8004 is a pan-kinase inhibitor and binds a range of tyrosine kinases, including ABL kinase. |
| FB11642 | BCR-ABL-IN-1 | 188260-50-6 | BCR-ABL-IN-1 is an inhibitor of BCR-ABL tyrosine kinase, with a pIC50 of 6.46, and may be used in the research of chronic myelogenous leukemia. |
| FB10793 | Bafetinib | 859212-16-1 | Bafetinib is a potent and selective dual Bcr-Abl/Lyn inhibitor with IC50 of 5.8 nM/19 nM in cell-free assays, does not inhibit the phosphorylation of the T315I mutant and is less potent to PDGFR and c-Kit. |
| FB10001 | Asciminib | 1492952-76-7 | Asciminib is a potent and selective allosteric Bcr-Abl inhibitor and inhibits Ba/F3 cells grown with an IC50 of 0.25 nM. |
| FB16525 | AP23848 | 834894-21-2 | AP23848 is a potent Bcr-Abl inhibitor. In a murine model, AP23848 inhibited activation-loop mutant Kit phosphorylation and tumor growth. |